Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Steno Diabetes Center Nordjylland | OTHER |
| Aalborg University | OTHER |
Not provided
Not provided
Not provided
This feasibility study will evaluate the feasibility of two telemonitoring designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.
Background: Maintaining optimal glycaemic control in type 2 diabetes (T2D) is difficult. Telemedicine has potential to support poorly controlled people with T2D in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. However, only few telemonitoring solutions for non-insulin treated T2D exist. Therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.
Method: The trial will be conducted as a three-month randomized feasibility study in four municipalities in North Denmark with 15 participants from each municipality. Two different telemonitoring intervention designs will be tested. One intervention will include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. The second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. Two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. Qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). In addition, differences in direct intervention costs between the two alternative interventions will be evaluated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telemonitoring design 1 | Experimental |
|
|
| Telemonitoring design 2 | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telemonitoring 1 | Other | This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity. |
| Measure | Description | Time Frame |
|---|---|---|
| Experiences with and acceptability of intervention design(s) | Qualitative interviews will be conducted with selected participants and HCPs to gain deeper insight into the participants and HCPs' experiences and acceptability with the two different telemonitoring intervention designs and the trial procedures. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the recruitment assessment 1 | Number (whole) of people agreeing to receive participant information letter about the study. | 1 month |
| Feasibility of the recruitment assessment 2 | Proportion (percentage) of people agreeing to receive participant information letter about the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Vestergaard, PhD (and MD) | Aalborg University Hospital and Steno Diabetes Center North Denmark | Principal Investigator |
| Sisse H Laursen, PhD | Aalborg University and Aalborg University Hospital | Study Chair |
| Stine Hangaard, PhD | Aalborg University and Steno Diabetes Center North Denmark | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Steno Diabetes Center North Denmark | Aalborg | 9000 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38778345 | Derived | Laursen SH, Giese IE, Udsen FW, Hejlesen OK, Barington PF, Ohrt M, Vestergaard P, Hangaard S. A telemonitoring intervention design for patients with poorly controlled type 2 diabetes: protocol for a feasibility study. Pilot Feasibility Stud. 2024 May 22;10(1):83. doi: 10.1186/s40814-024-01509-0. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Telemonitoring 2 | Other | This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. |
|
| 1 month |
| Feasibility of the recruitment assessment 3 | Number (whole) of eligible participants who agree to participate. | 1 month |
| Feasibility of the recruitment assessment 4 | Proportion (percentage) of eligible participants who agree to participate. | 1 month |
| Feasibility of the recruitment assessment 5 | Potential inequalities regarding recruitment feasibility assessed by comparing those who accepted participation to those who declined with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L). | 1 month |
| Retention assessment 1 | Number (whole) of participants withdrawing from the trial. | 3 months |
| Retention assessment 2 | Proportion (percentage) of participants withdrawing from the trial. | 3 months |
| Retention assessment 3 | Timepoint(s) for withdrawal. | 3 months |
| Retention assessment 4 | Reasons of discontinuation of the trial. | 3 months |
| Retention assessment 5 | Potential inequalities regarding retention feasibility assessed by comparing those who retented participation to those who withdrawal with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L). | 3 months |
| Adherence to answering the questionnaire: Diabetes-related quality of life: The Problem Areas in Diabetes Questionnaire (PAID-5) | The respons rate for PAID-5 at baseline and at 3 months, respectively. | At baseline (T0) and 3 months (T1) |
| Adherence to answering the questionnaire: Quality of Life: The Short Form 12 Questionnaire (SF-12v2) | The respons rate for SF-12v2 at baseline and at 3 months, respectively. | At baseline (T0) and 3 months (T1) |
| Adherence to answering the questionnaire: Well-being: The World Health Organization Five Well-being Index (WHO-5) | The respons rate for WHO-5 at baseline and at 3 months, respectively. | At baseline (T0) and 3 months (T1) |
| Adherence to answering the questionnaire: The Patient Activation Measure questionnaire (PAM) | The respons rate for PAM at baseline and at 3 months, respectively. | At baseline (T0) and 3 months (T1) |
| Challenges in the blood sampling schedule | Explore through qualitative interviews whether there are any analysis challenges or uncertainties in the clinical workflow with regard to the blood sampling schedule. | At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3) |
| Adherence to the blood sampling schedule | Number and proportion of the participants who completes the blood sampling at baseline, 3 months, 6 months, and 12 months, respectively. | At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3) |
| Costs | Differences in direct intervention costs between the two alternatives. Resource categories are comprised of equipment and time spent on monitoring, time spent training patients in using the equipment, and potential additional training for community nurses. Resources will be evaluated as prices paid and hourly wages and represented as equivalent annual costs in 2023 prices. | 12 months |